- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000639
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole.
At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.
Patients are selected by a randomization process to take amphotericin B intravenously (in the vein), for 14 days, and either placebo (ineffective substance) or flucytosine for 14 days. Then patients are again selected by a randomization process to take either (1) fluconazole for a total of 8 weeks plus itraconazole placebo; or (2) itraconazole for a total of 8 weeks plus fluconazole placebo.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC CRS
-
San Francisco, California, United States, 94110
- Ucsf Aids Crs
-
-
Florida
-
Miami, Florida, United States, 33136
- Univ. of Miami AIDS CRS
-
-
Hawaii
-
Honolulu, Hawaii, United States
- Univ. of Hawaii at Manoa, Leahi Hosp.
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University CRS
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
-
Indianapolis, Indiana, United States, 46202
- Methodist Hosp. of Indiana
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital ACTG CRS
-
Boston, Massachusetts, United States, 02118
- Bmc Actg Crs
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Med. Ctr., ACTG CRS
-
-
Missouri
-
Saint Louis, Missouri, United States
- Washington U CRS
-
Saint Louis, Missouri, United States
- St. Louis ConnectCare, Infectious Diseases Clinic
-
-
New York
-
Buffalo, New York, United States, 14215
- SUNY - Buffalo, Erie County Medical Ctr.
-
New York, New York, United States, 10021
- Cornell University A2201
-
New York, New York, United States, 10003
- Beth Israel Med. Ctr. (Mt. Sinai)
-
Rochester, New York, United States, 14642
- Univ. of Rochester ACTG CRS
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Unc Aids Crs
-
Charlotte, North Carolina, United States
- Carolinas HealthCare System, Carolinas Med. Ctr.
-
Greensboro, North Carolina, United States, 27401
- Regional Center for Infectious Disease, Wendover Medical Center CRS
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Univ. of Cincinnati CRS
-
Columbus, Ohio, United States, 43210
- The Ohio State Univ. AIDS CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hosp. of the Univ. of Pennsylvania CRS
-
Pittsburgh, Pennsylvania, United States, 15213
- Pitt CRS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Interruption of myelosuppressive therapies and/or administration of erythropoietin, at discretion of investigator, to maintain hemoglobin = or > 7 g/dl.
- Adjunctive corticosteroids may be administered during the triazole phase for patients who develop Pneumocystis carinii pneumonia and meet the prescribed criteria.
- Hydrocortisone, not to exceed 50 mg/day, during the amphotericin phase.
- Aerosolized pentamidine or systemic chemoprophylaxis for Pneumocystis carinii pneumonia should be given to all patients with a CD4 count < 200 cells/mm3.
- Antiretroviral drugs (including zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC)) after patient has tolerated oral triazole for one week (after 3 weeks of study treatment).
- Maintenance treatment (except for rifamycins) for other opportunistic infections such as cytomegalovirus (CMV) retinitis, cerebral toxoplasmosis or mycobacterial infections, provided that their hematologic and hepatic values are stable and they meet the entry criteria.
Concurrent Treatment:
Allowed:
- Transfusion, at discretion of investigator, to maintain hemoglobin = or > 7 g/dl.
Patients must have:
- HIV infection.
- Primary episode of acute cryptococcal meningitis.
- Willing to participate in the study for a full 10 weeks and either be able to give informed consent or have a family member or guardian able to give informed consent.
Prior Medication:
Allowed:
Fluconazole prophylaxis, not exceeding 200 mg/day.
Risk Behavior:
Allowed:
- History of high-risk behavior for HIV infection (bisexual or homosexual men, intravenous drug abusers) and their sexual partners.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Inability to take oral medication (if necessary, flucytosine and flucytosine placebo may be administered via nasogastric tube during the amphotericin phase).
- History of hypersensitivity to imidazole or triazole compounds.
- Active hepatitis (viral, drug-induced, or other) defined by progressive worsening of hepatic enzymes to grade 3 or 4 toxicity on at least two occasions.
- Comatose.
- Concurrent CNS disease which, in the opinion of the investigator, would interfere with assessment of response.
Concurrent Medication:
Excluded:
- Continued treatment with H2 blockers (ranitidine (Zantac), cimetidine (Tagamet), omeprazole (Prilosec), nizatidine (Axid), famotidine (Pepcid)).
- Antacids and didanosine (ddI) within 2 hours of triazole administration.
- Rifampin, rifabutin (Ansamycin), and other rifamycin derivatives, phenytoin (Dilantin), phenobarbital, or carbamazepine (Tegretol).
- Other systemic antifungal agents.
Prior Medication:
Excluded:
- Amphotericin, > 1 mg/kg, or fluconazole or ketoconazole, > 1200 mg, as prior treatment for current primary episode of acute cryptococcal meningitis or treatment started for this episode more than 72 hours prior to enrollment into study.
- Phenytoin (Dilantin), carbamazepine (Tegretol), phenobarbital, rifabutin (Ansamycin), rifampin or other rifamycins within the last 15 days.
Patients may not have:
- Inability to take oral medication (if necessary, flucytosine and flucytosine placebo may be administered via nasogastric tube during the amphotericin phase).
- History of hypersensitivity to imidazole or triazole compounds.
- Active hepatitis.
- Patients who are comatose.
- Concurrent CNS disease which, in the opinion of the investigator, would interfere with assessment of response.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: van der Horst C
- Study Chair: Saag M
Publications and helpful links
General Publications
- van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997 Jul 3;337(1):15-21. doi: 10.1056/NEJM199707033370103.
- Powderly WG. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996 May;22 Suppl 2:S119-23. doi: 10.1093/clinids/22.supplement_2.s119.
- Powderly WG, Tuazon C, Cloud GA, Saag MS, Van Der Horst C. Serum and CSF cryptococcal antigen in management of cryptococcal meningitis in AIDS. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:66 (abstract no 6)
Study record dates
Study Major Dates
Study Start
Primary Completion
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Bacterial Infections and Mycoses
- Mycoses
- Meningitis, Fungal
- Central Nervous System Fungal Infections
- Cryptococcosis
- Meningitis
- Meningitis, Cryptococcal
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antimetabolites
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Amebicides
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Itraconazole
- Fluconazole
- Flucytosine
- Amphotericin B
- Liposomal amphotericin B
Other Study ID Numbers
- ACTG 159
- FDA 235A
- MSG Study 17
- 11134 (DAIDS ES Registry Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Fluconazole
-
AstraZenecaCompletedAsthmaUnited States, Canada, Denmark, France, Italy, Sweden, United Kingdom, Belgium, Taiwan, Brazil, Poland, Russian Federation, Spain, Germany, Argentina, Colombia, Mexico
-
National Hospital for Tropical Diseases, Hanoi,...Centers for Disease Control and Prevention; Hospital for Tropical Diseases,...UnknownHIV/AIDS | Mycosis Fungoides | Cryptococcosis | Cryptococcal Meningitis | Opportunistic Infections, HIV Related | Mycosis; OpportunisticVietnam
-
Radboud University Medical CenterSt. Antonius HospitalCompletedObesity | Candidiasis | Invasive Fungal Infections | FluconazoleNetherlands
-
Daniel BenjaminPediatric Pharmacology Research Units NetworkCompletedCandidiasisUnited States
-
BayerCompletedPharmacology, ClinicalGermany
-
PfizerCompleted
-
Anders Rane, MD, PhD, Senior professorKarolinska University HospitalCompletedBacterial Infections and Mycoses | Ductus Arteriosis, PatentSweden
-
Makerere UniversityGilead Sciences; University of MinnesotaRecruitingCryptococcal MeningitisUganda
-
F2G Biotech GmbHThe Clinical Trials Centre Cologne; Klinik für Hämatologie, Aachen; Medizinische...Withdrawn
-
Benha UniversityRecruiting